Deutsche Biotech-Hoffnung Tubulis holt Top-Investoren an Bord – Börsengang ist "immer eine Option"
Der Markt für Antikörper-Wirkstoff-Konjugate, den sogenannten ADCs, bleibt siedend heiß. In den USA gab es in den vergangenen Quartalen in…
168,580€
0,85%
Echtzeit-Aktienkurs Abbvie Inc.
Bid:
Ask:
Nachrichten zur Abbvie Inc. Aktie
Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast…
AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease
For Medical and Trade media.
· Foslevodopa-foscarbidopa will soon be available for eligible patients with advanced levodopa-responsive Parkinson’s disease…
AbbVie Inc. (ABBV) TD Cowen 44th Annual Health Care Conference (Transcript)
…
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
The FDA grants priority review status to Sanofis (SNY) and AbbVies (ABBV) sBLAs for Dupixent and Epkinly, respectively…
AbbVie and OSE Immunotherapeutics ink $713M deal By Investing.com
AbbVie and OSE Immunotherapeutics ink $713M deal…
Healthcare Stocks: 5 Biggest Companies in 2024
Healthcare is one of the worlds most critical sectors, and healthcare stocks offer an opportunity to invest in companies that…
AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel
Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help…
AbbVie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports By Reuters
AbbVie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports…
AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A
Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions…
AbbVie: Pharma-Riese auf Shopping-Tour - Aktienanalyse
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Robert Michael is set to succeed Richard A. Gonzalez as AbbVies (ABBV) CEO, effective Jul 1, 2024.…
AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez
Michael, who is AbbVies chief operating officer, will become the companys second-ever CEO since the company spun out from Abbott…
AbbVie names Robert A. Michael as new CEO By Investing.com
AbbVie names Robert A. Michael as new CEO…
Cerevel, AbbVie get FTC Second Requests for more merger info
…
AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen
AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of…
Top Stock Reports for AbbVie, Applied Materials & American Express
Todays Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Applied Materials, Inc. (AMAT) and…
These 17 Words From AbbVies CEO Explain Why the Stock Is Still a Buy
The drugmaker is handling its biggest obstacle yet relatively well.…
Pharma Stocks: 5 Biggest Companies in 2024
The pharmaceutical industry is a major player in the life science sector, responsible for developing and manufacturing the majority of…
ImmunoGen spikes as HSR waiting period for AbbVie deal expires
…
Analysts revamp AbbVie stock price target after earnings report
Heres what could happen to AbbVies shares next.…
Better Dividend Stock: Pfizer vs. AbbVie
Both offer above-average yields but which can deliver the most dividend income over the long run?…
Better Dividend Stock: Pfizer vs. AbbVie
…
Überzeugende Zahlen von Meta Platforms - Jahreszahlen von AbbVie erfüllen Erwartungen
Wien (www.aktiencheck.de) - AbbVie (ISIN: US00287Y1091, WKN: A1J84E, Ticker-Symbol: 4AB, NYSE-Symbol: ABBV) (+0,6%) stellte ebenfalls am Freitag seine Jahreszahlen vor,…
AbbVie (ABBV) Q4 2023 Earnings Call Transcript
ABBV earnings call for the period ending December 31, 2023.…
AbbVie cites tailwinds to Botox business from weight loss drugs
…
AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript
…
Here are Jim Cramer’s rapid-fire takeaways on 6 stocks in the news Friday
Morning Meeting updates on stocks outside the Club portfolio: Clorox, Tesla, Bristol-Myers, Abbvie, Exxon and Chevron.…
Bristol Meyers Squibb, AbbVie top 4Q sales and profit estimates
Drugmakers Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) and Abbvie Inc (NYSE:ABBV) on Friday both reported better than expected financial results...…
AbbVie: Eine Zukunft ohne Humira - Aktienanalyse
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…
AbbVie tops Q4 earnings, revenue consensus estimate By Investing.com
AbbVie tops Q4 earnings, revenue consensus estimate…
AbbVie earnings beat by $0.02, revenue topped estimates By Investing.com
AbbVie earnings beat by $0.02, revenue topped estimates…
AbbVie reports mixed Q4 results; raises FY24 outlook
…
AbbVie earnings missed by $0.04, revenue topped estimates By Investing.com
AbbVie earnings missed by $0.04, revenue topped estimates…
AbbVie’s fourth-quarter sales top estimates despite plunging Humira revenues
AbbVie on Friday reported fourth-quarter sales that topped analyst estimates, even as it faces low-cost competition for its top-seller Humira.…
AbbVie profit beats on better-than-expected Humira, Botox sales
…
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals By Reuters
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals…
Übernahme von Botox-Hersteller gibt AbbVie Schub
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Agentur - Boehringer und AbbVie in Gesprächen über Krebs-Allianz
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…